Market Overview

ACADIA Pharma Shares Move Higher as JMP Boosted Price Target from $16 to $27

Share:
Related ACAD
Viking Global Liked AIG, Google, Actavis, Illumina And Cheniere Energy Last Quarter
Benzinga's Top Initiations
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q1 2015 Update (Seeking Alpha)

JMP Securities maintains ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) with a Market Outperform and raises the price target from $16.00 to $27.00.

The stock has opened up more than 4 percent higher. With the stock last trading at $19.45, the firm's new price target implies potential upside of about 39 percent.

Latest Ratings for ACAD

DateFirmActionFromTo
May 2015JP MorganMaintainsOverweight
Apr 2015Leerink SwannInitiates Coverage onOutperform
Mar 2015JefferiesMaintainsBuy

View More Analyst Ratings for ACAD
View the Latest Analyst Ratings

Posted-In: News Price Target Analyst Ratings

 

Related Articles (ACAD)

Around the Web, We're Loving...

Get Benzinga's Newsletters